



Company profile

Deflexifol is our most advanced drug reformulation and has the potential to improve treatment outcomes for patients with metastatic disease. Fivephusion Pty Ltd aims to develop and commercialise proprietary reformulations of widely prescribed anti-metabolic agents targeting solid tissue cancers. Deflexifol is available for licencing or a commercialisation partnership.

Fusing the cornerstone chemotherapeutic drugs 5-fluorouracil and leucovorin, Deflexifol offers the following benefits in treating colo-rectal cancer (CRC):

- potentially increased efficacy over standard treatments
- simultaneous administration of all therapeutic ingredients
- significantly reduced toxicity
- scalable production
- low cost of manufacturing materials.

Speaker Profile



David Ranson is Chairman of FivepHusion Pty Ltd, and leads its business development, regulatory and commercialisation efforts. He has successfully outlicensed Deflexifol from the University of Wollongong, and overseen fund-raising for and management of the phase 1b/2a clinical trial of the drug. He has been a director of several proprietary companies over the past 28 years. Since graduating in 1986 BE (Hons 1) UNSW, David has worked in product development in both Australia and the USA.